Integrating diverse layers of omic data to identify novel drug targets in Listeria monocytogenes

Miranda C. Palumbo, E. Sosa, Florencia A Castello, Gustavo Schottlender, F. Serral, A. Turjanski, M. M. Palomino, D. F. Do Porto
{"title":"Integrating diverse layers of omic data to identify novel drug targets in Listeria monocytogenes","authors":"Miranda C. Palumbo, E. Sosa, Florencia A Castello, Gustavo Schottlender, F. Serral, A. Turjanski, M. M. Palomino, D. F. Do Porto","doi":"10.3389/fddsv.2022.969415","DOIUrl":null,"url":null,"abstract":"Listeria monocytogenes (Lm) is a Gram-positive bacillus responsible for listeriosis in humans. Listeriosis has become a major foodborne illness in recent years. This illness is mainly associated with the consumption of contaminated food and ready-to-eat products. Recently, Lm has developed resistances to a broad range of antimicrobials, including those used as the first choice of therapy. Moreover, multidrug-resistant strains have been detected in clinical isolates and settings associated with food processing. This scenario punctuates the need for novel antimicrobials against Lm. On the other hand, increasingly available omics data for diverse pathogens has created new opportunities for rational drug discovery. Identification of an appropriate molecular target is currently accepted as a critical step of this process. In this work, we generated multiple layers of omics data related to Lm, aiming to prioritize proteins that could serve as attractive targets for antimicrobials against L. monocytogenes. We generated genomic, transcriptomic, metabolic, and protein structural information, and this data compendium was integrated onto a freely available web server (Target Pathogen). Thirty targets with desirable features from a drug development point of view were shortlisted. This set of target proteins participates in key metabolic processes such as fatty acid, pentose, rhamnose, and amino acids metabolism. Collectively, our results point towards novel targets for the control of Lm and related bacteria. We invite researchers working in the field of drug discovery to follow up experimentally on our revealed targets.","PeriodicalId":73080,"journal":{"name":"Frontiers in drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fddsv.2022.969415","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Listeria monocytogenes (Lm) is a Gram-positive bacillus responsible for listeriosis in humans. Listeriosis has become a major foodborne illness in recent years. This illness is mainly associated with the consumption of contaminated food and ready-to-eat products. Recently, Lm has developed resistances to a broad range of antimicrobials, including those used as the first choice of therapy. Moreover, multidrug-resistant strains have been detected in clinical isolates and settings associated with food processing. This scenario punctuates the need for novel antimicrobials against Lm. On the other hand, increasingly available omics data for diverse pathogens has created new opportunities for rational drug discovery. Identification of an appropriate molecular target is currently accepted as a critical step of this process. In this work, we generated multiple layers of omics data related to Lm, aiming to prioritize proteins that could serve as attractive targets for antimicrobials against L. monocytogenes. We generated genomic, transcriptomic, metabolic, and protein structural information, and this data compendium was integrated onto a freely available web server (Target Pathogen). Thirty targets with desirable features from a drug development point of view were shortlisted. This set of target proteins participates in key metabolic processes such as fatty acid, pentose, rhamnose, and amino acids metabolism. Collectively, our results point towards novel targets for the control of Lm and related bacteria. We invite researchers working in the field of drug discovery to follow up experimentally on our revealed targets.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
整合不同层次的组学数据以确定单核细胞增多性李斯特菌的新药物靶点
单核细胞增多性李斯特菌(Lm)是一种引起人类李斯特菌病的革兰氏阳性杆菌。李斯特菌病近年来已成为一种主要的食源性疾病。这种疾病主要与食用受污染的食品和即食产品有关。最近,Lm对多种抗菌药物产生了耐药性,包括那些作为首选治疗药物的抗菌药物。此外,在与食品加工相关的临床分离株和环境中检测到了耐多药菌株。这种情况强调了对Lm新型抗菌药物的需求。另一方面,越来越多的不同病原体的组学数据为合理的药物发现创造了新的机会。鉴定合适的分子靶标目前被认为是这一过程的关键步骤。在这项工作中,我们生成了与Lm相关的多层组学数据,旨在优先考虑可以作为抗单核细胞增多性李斯特菌的有吸引力的靶点的蛋白质。我们生成了基因组、转录组、代谢和蛋白质结构信息,这些数据汇编被集成到一个免费的网络服务器(目标病原体)上。从药物开发的角度来看,有30个具有理想特征的靶点入围。这组靶蛋白参与关键的代谢过程,如脂肪酸、戊糖、鼠李糖和氨基酸代谢。总之,我们的研究结果指向了控制Lm和相关细菌的新靶点。我们邀请在药物发现领域工作的研究人员对我们揭示的靶点进行实验跟踪。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Mimicking the immunosuppressive impact of fibroblasts in a 3D multicellular spheroid model Alternative therapeutics to control antimicrobial resistance: a general perspective Editorial: The boulder peptide symposium 2021 scientific update Applying artificial intelligence to accelerate and de-risk antibody discovery Editorial: Women in anti-inflammatory and immunomodulating agents: 2022
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1